FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 309:883-887 October 13, 1983 Number 15 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

The murine monoclonal antibody OC 125 reacts with an antigen (CA 125) common to most nonmucinous epithelial ovarian carcinomas. An assay has been developed to detect CA 125 in serum. By this assay, only 1 per cent of 888 apparently healthy persons and 6 per cent of 143 patients with nonmalignant disease had serum CA 125 levels above 35 U per milliliter. In contrast, 83 of 101 patients (82 per cent) with surgically demonstrated ovarian carcinoma had elevated levels of antigen. In 38 patients with epithelial ovarian carcinoma monitored on 2 to 18 occasions during 2 to 60 months, antigen levels ranged from less than 1 to more than 8000 U per milliliter. Rising or falling levels of CA 125 correlated with progression or regression of disease in 42 of 45 instances (93 per cent). Determination of CA 125 levels may aid in monitoring the response to treatment in patients with epithelial ovarian cancer.

This article has been cited by other articles:

• Gowri, V., Jain, R. (2009). Investigating infertility. BMJ 339: b3390-b3390 [Full Text]  
• Clarke-Pearson, D. L. (2009). Screening for Ovarian Cancer. NEJM 361: 170-177 [Full Text]  
• MAHNER, S., WOELBER, L., JUNG, S., EULENBURG, C. Z., IHNEN, M., SCHWARZ, J., SEHOULI, J., JAENICKE, F. (2009). Prognostic Significance of CA-125 in the Management of Patients with Recurrent Epithelial Ovarian Carcinoma Selected for Secondary Cytoreduction. Anticancer Res 29: 2817-2821 [Abstract] [Full Text]  
• Kaneko, O., Gong, L., Zhang, J., Hansen, J. K., Hassan, R., Lee, B., Ho, M. (2009). A Binding Domain on Mesothelin for CA125/MUC16. J. Biol. Chem. 284: 3739-3749 [Abstract] [Full Text]  
• Drapkin, R., Clauss, A., Skates, S. (2008). Urokinase-Type Plasminogen Activator Receptor: A Beacon of Malignancy?. Clin. Cancer Res. 14: 5643-5645 [Abstract] [Full Text]  
• Mall, A S (2008). Analysis of mucins: role in laboratory diagnosis. J. Clin. Pathol. 61: 1018-1024 [Abstract] [Full Text]  
• Scholler, N., Lowe, K. A., Bergan, L. A., Kampani, A. V., Ng, V., Forrest, R. M., Thorpe, J. D., Gross, J. A., Garvik, B. M., Drapkin, R., Anderson, G. L., Urban, N. (2008). Use of Yeast-Secreted In vivo Biotinylated Recombinant Antibodies (Biobodies) in Bead-Based ELISA. Clin. Cancer Res. 14: 2647-2655 [Abstract] [Full Text]  
• Prat, A., Parera, M., Peralta, S., Perez-Benavente, M. A., Garcia, A., Gil-Moreno, A., Martinez-Palones, J. M., Roxana, I., Baselga, J., Del Campo, J. M. (2008). Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol 19: 327-331 [Abstract] [Full Text]  
• Van Calster, B., Timmerman, D., Bourne, T., Testa, A. C., Van Holsbeke, C., Domali, E., Jurkovic, D., Neven, P., Van Huffel, S., Valentin, L. (2007). Discrimination Between Benign and Malignant Adnexal Masses by Specialist Ultrasound Examination Versus Serum CA-125. JNCI J Natl Cancer Inst 99: 1706-1714 [Abstract] [Full Text]  
• Hudson, M. E., Pozdnyakova, I., Haines, K., Mor, G., Snyder, M. (2007). Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc. Natl. Acad. Sci. USA 104: 17494-17499 [Abstract] [Full Text]  
• Timmerman, D., Van Calster, B., Jurkovic, D., Valentin, L., Testa, A. C., Bernard, J.-P., Van Holsbeke, C., Van Huffel, S., Vergote, I., Bourne, T. (2007). Inclusion of CA-125 Does Not Improve Mathematical Models Developed to Distinguish Between Benign and Malignant Adnexal Tumors. JCO 25: 4194-4200 [Abstract] [Full Text]  
• Moore, R. G., Bast, R. C. Jr (2007). How Do You Distinguish a Malignant Pelvic Mass From a Benign Pelvic Mass? Imaging, Biomarkers, or None of the Above. JCO 25: 4159-4161 [Full Text]  
• Nunez, J., Nunez, E., Consuegra, L., Sanchis, J., Bodi, V., Martinez-Brotons, A., Bertomeu-Gonzalez, V., Robles, R., Bosch, M. J, Facila, L., Darmofal, H., Llacer, A. (2007). Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure?. Heart 93: 716-721 [Abstract] [Full Text]  
• Aletti, G. D., Gallenberg, M. M., Cliby, W. A., Jatoi, A., Hartmann, L. C. (2007). Current Management Strategies for Ovarian Cancer. Mayo Clin Proc. 82: 751-770 [Abstract] [Full Text]  
• Vasmatzis, G., Klee, E. W., Kube, D. M., Therneau, T. M., Kosari, F. (2007). Quantitating tissue specificity of human genes to facilitate biomarker discovery. Bioinformatics 23: 1348-1355 [Abstract] [Full Text]  
• Lambeck, A. J.A., Crijns, A. P.G., Leffers, N., Sluiter, W. J., ten Hoor, K. A., Braid, M., van der Zee, A. G.J., Daemen, T., Nijman, H. W., Kast, W. M. (2007). Serum Cytokine Profiling as a Diagnostic and Prognostic Tool in Ovarian Cancer: A Potential Role for Interleukin 7. Clin. Cancer Res. 13: 2385-2391 [Abstract] [Full Text]  
• Martinez, S., Garrido, N., Coperias, J.L., Pardo, F., Desco, J., Garcia-Velasco, J.A., Simon, C., Pellicer, A. (2007). Serum interleukin-6 levels are elevated in women with minimal-mild endometriosis. Hum Reprod 22: 836-842 [Abstract] [Full Text]  
• Pothacharoen, P., Siriaunkgul, S., Ong-Chai, S., Supabandhu, J., Kumja, P., Wanaphirak, C., Sugahara, K., Hardingham, T., Kongtawelert, P. (2006). Raised Serum Chondroitin Sulfate Epitope Level in Ovarian Epithelial Cancer. J Biochem 140: 517-524 [Abstract] [Full Text]  
• Borowsky, M. E., Das, B., Axiotis, C. A., Malka, E. S., Abulafia, O., Norin, A. J. (2006). Haymaker Gene Expression in Malignant and Normal Gynecologic Tissues. J. Histochem. Cytochem. 54: 753-761 [Abstract] [Full Text]  
• Nagler, R., Bahar, G., Shpitzer, T., Feinmesser, R. (2006). Concomitant Analysis of Salivary Tumor Markers--A New Diagnostic Tool for Oral Cancer.. Clin. Cancer Res. 12: 3979-3984 [Abstract] [Full Text]  
• Kosar, F., Aksoy, Y., Ozguntekin, G., Ozerol, I., Varol, E. (2006). Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail 8: 270-274 [Abstract] [Full Text]  
• Rustin, G. J.S., Timmers, P., Nelstrop, A., Shreeves, G., Bentzen, S. M., Baron, B., Piccart, M. J., Bertelsen, K., Stuart, G., Cassidy, J., Eisenhauer, E. (2006). Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide. JCO 24: 45-51 [Abstract] [Full Text]  
• Santillan, A., Garg, R., Zahurak, M. L., Gardner, G. J., Giuntoli, R. L. II, Armstrong, D. K., Bristow, R. E. (2005). Risk of Epithelial Ovarian Cancer Recurrence in Patients With Rising Serum CA-125 Levels Within the Normal Range. JCO 23: 9338-9343 [Abstract] [Full Text]  
• Kalambokis, G., Kostoula, A., Economou, M., Tsianos, E. V. (2005). Tumor Necrosis Factor-{alpha}-Related Intraperitoneal Release of CA 125 in Cirrhotic Patients with Sterile Ascites. Clin. Chem. 51: 2207-2208 [Full Text]  
• Paramasivam, S., Tripcony, L., Crandon, A., Quinn, M., Hammond, I., Marsden, D., Proietto, A., Davy, M., Carter, J., Nicklin, J., Perrin, L., Obermair, A. (2005). Prognostic Importance of Preoperative CA-125 in International Federation of Gynecology and Obstetrics Stage I Epithelial Ovarian Cancer: An Australian Multicenter Study. JCO 23: 5938-5942 [Abstract] [Full Text]  
• Jankovic, M. M., Tapuskovic, B. S. (2005). Molecular forms and microheterogeneity of the oligosaccharide chains of pregnancy-associated CA125 antigen. Hum Reprod 20: 2632-2638 [Abstract] [Full Text]  
• Peters, D. G., Kudla, D. M., DeLoia, J. A., Chu, T. J., Fairfull, L., Edwards, R. P., Ferrell, R. E. (2005). Comparative Gene Expression Analysis of Ovarian Carcinoma and Normal Ovarian Epithelium by Serial Analysis of Gene Expression. Cancer Epidemiol. Biomarkers Prev. 14: 1717-1723 [Abstract] [Full Text]  
• Kitawaki, J., Ishihara, H., Koshiba, H., Kiyomizu, M., Teramoto, M., Kitaoka, Y., Honjo, H. (2005). Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas. Hum Reprod 20: 1999-2003 [Abstract] [Full Text]  
• Bondurant, K. L., Crew, M. D., Santin, A. D., O'Brien, T. J., Cannon, M. J. (2005). Definition of an Immunogenic Region Within the Ovarian Tumor Antigen Stratum Corneum Chymotryptic Enzyme. Clin. Cancer Res. 11: 3446-3454 [Abstract] [Full Text]  
• Kouris, N. T., Zacharos, I. D., Kontogianni, D. D., Goranitou, G. S., Sifaki, M. D., Grassos, H. E., Kalkandi, E. M., Babalis, D. K. (2005). The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 7: 199-203 [Abstract] [Full Text]  
• Baron, A. T., Boardman, C. H., Lafky, J. M., Rademaker, A., Liu, D., Fishman, D. A., Podratz, K. C., Maihle, N. J. (2005). Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer. Cancer Epidemiol. Biomarkers Prev. 14: 306-318 [Abstract] [Full Text]  
• Faggiano, P., D'Aloia, A., Brentana, L., Bignotti, T., Fiorina, C., Vizzardi, E., Cas, L. D. (2005). Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail 7: 57-61 [Abstract] [Full Text]  
• Cannistra, S. A. (2004). Cancer of the Ovary. NEJM 351: 2519-2529 [Full Text]  
• Rustin, G. J.S. (2004). Can We Now Agree to Use the Same Definition to Measure Response According to CA-125?. JCO 22: 4035-4036 [Full Text]  
• Skates, S., Iliopoulos, O. (2004). Molecular Markers for Early Detection of Renal Carcinoma: Investigative Approach. Clin. Cancer Res. 10: 6296S-6301S [Abstract] [Full Text]  
• Berek, J. S., Taylor, P. T., Gordon, A., Cunningham, M. J., Finkler, N., Orr, J. Jr, Rivkin, S., Schultes, B. C., Whiteside, T. L., Nicodemus, C. F. (2004). Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer. JCO 22: 3507-3516 [Abstract] [Full Text]  
• Dupont, J., Tanwar, M. K., Thaler, H. T., Fleisher, M., Kauff, N., Hensley, M. L., Sabbatini, P., Anderson, S., Aghajanian, C., Holland, E. C., Spriggs, D. R. (2004). Early Detection and Prognosis of Ovarian Cancer Using Serum YKL-40. JCO 22: 3330-3339 [Abstract] [Full Text]  
• Paju, A., Vartiainen, J., Haglund, C., Itkonen, O., von Boguslawski, K., Leminen, A., Wahlstrom, T., Stenman, U.-H. (2004). Expression of Trypsinogen-1, Trypsinogen-2, and Tumor-Associated Trypsin Inhibitor in Ovarian Cancer: Prognostic Study on Tissue and Serum. Clin. Cancer Res. 10: 4761-4768 [Abstract] [Full Text]  
• Rustin, G. J. S., Bast, R. C. Jr., Kelloff, G. J., Barrett, J. C., Carter, S. K., Nisen, P. D., Sigman, C. C., Parkinson, D. R., Ruddon, R. W. (2004). Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer. Clin. Cancer Res. 10: 3919-3926 [Full Text]  
• Schorge, J. O., Drake, R. D., Lee, H., Skates, S. J., Rajanbabu, R., Miller, D. S., Kim, J.-H., Cramer, D. W., Berkowitz, R. S., Mok, S. C. (2004). Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer. Clin. Cancer Res. 10: 3474-3478 [Abstract] [Full Text]  
• Nouriani, M., Bahador, A., Berek, J. S., Cheng, J. P., Chi, D. S., Cliby, W. A., Del Priore, G., Dodson, M. K., Duggan, B. D., Gershenson, D. M., Lentz, S. E., Penson, R. T., Robinson, W. R., Rodriguez, M., Roman, L. D., Yu, M. C., Zempolich, K., Dubeau, L. (2004). Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy. Clin. Cancer Res. 10: 2681-2686 [Abstract] [Full Text]  
• Jacobs, I. J., Menon, U. (2004). Progress and Challenges in Screening for Early Detection of Ovarian Cancer. Mol. Cell. Proteomics 3: 355-366 [Abstract] [Full Text]  
• Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N., Takeuchi, M., Miyajima, A. (2004). Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion. J. Biol. Chem. 279: 9190-9198 [Abstract] [Full Text]  
• Kato, H., Hatori, M., Kokubun, S., Watanabe, M., Smith, R. A, Hotta, T., Ogose, A., Morita, T., Murakami, T., Aiba, S. (2004). CA125 Expression in Epithelioid Sarcoma. Jpn J Clin Oncol 34: 149-154 [Abstract] [Full Text]  
• Kozak, K. R., Amneus, M. W., Pusey, S. M., Su, F., Luong, M. N., Luong, S. A., Reddy, S. T., Farias-Eisner, R. (2003). Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis. Proc. Natl. Acad. Sci. USA 100: 12343-12348 [Abstract] [Full Text]  
• Ye, B., Cramer, D. W., Skates, S. J., Gygi, S. P., Pratomo, V., Fu, L., Horick, N. K., Licklider, L. J., Schorge, J. O., Berkowitz, R. S., Mok, S. C. (2003). Haptoglobin-{alpha} Subunit As Potential Serum Biomarker in Ovarian Cancer: Identification and Characterization Using Proteomic Profiling and Mass Spectrometry. Clin. Cancer Res. 9: 2904-2911 [Abstract] [Full Text]  
• Kui Wong, N., Easton, R. L., Panico, M., Sutton-Smith, M., Morrison, J. C., Lattanzio, F. A., Morris, H. R., Clark, G. F., Dell, A., Patankar, M. S. (2003). Characterization of the Oligosaccharides Associated with the Human Ovarian Tumor Marker CA125. J. Biol. Chem. 278: 28619-28634 [Abstract] [Full Text]  
• Petricoin, E. F., Liotta, L. A. (2003). Clinical Applications of Proteomics. J. Nutr. 133: 2476S-2484 [Abstract] [Full Text]  
• Argueso, P., Spurr-Michaud, S., Russo, C. L., Tisdale, A., Gipson, I. K. (2003). MUC16 Mucin Is Expressed by the Human Ocular Surface Epithelia and Carries the H185 Carbohydrate Epitope. IOVS 44: 2487-2495 [Abstract] [Full Text]  
• D'Aloia, A., Faggiano, P., Aurigemma, G., Bontempi, L., Ruggeri, G., Metra, M., Nodari, S., Dei Cas, L. (2003). Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: Relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 41: 1805-1811 [Abstract] [Full Text]  
• Rustin, G. J.S. (2003). Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials. JCO 21: 187s-193 [Abstract] [Full Text]  
• Bast, R. C. Jr (2003). Status of Tumor Markers in Ovarian Cancer Screening. JCO 21: 200s-205 [Abstract] [Full Text]  
• Yousef, G. M., Polymeris, M.-E., Yacoub, G. M., Scorilas, A., Soosaipillai, A., Popalis, C., Fracchioli, S., Katsaros, D., Diamandis, E. P. (2003). Parallel Overexpression of Seven Kallikrein Genes in Ovarian Cancer. Cancer Res. 63: 2223-2227 [Abstract] [Full Text]  
• Seelenmeyer, C., Wegehingel, S., Lechner, J., Nickel, W. (2003). The cancer antigen CA125 represents a novel counter receptor for galectin-1. J. Cell Sci. 116: 1305-1318 [Abstract] [Full Text]  
• Diamandis, E. P., Scorilas, A., Fracchioli, S., van Gramberen, M., de Bruijn, H., Henrik, A., Soosaipillai, A., Grass, L., Yousef, G. M., Stenman, U.-H., Massobrio, M., van der Zee, A. G., Vergote, I., Katsaros, D. (2003). Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma. JCO 21: 1035-1043 [Abstract] [Full Text]  
• Kato, H., Hatori, M., Watanabe, M., Kokubun, S. (2003). Epithelioid Sarcomas with Elevated Serum CA125: Report of Two Cases. Jpn J Clin Oncol 33: 141-144 [Abstract] [Full Text]  
• Luo, L.-Y., Katsaros, D., Scorilas, A., Fracchioli, S., Bellino, R., van Gramberen, M., de Bruijn, H., Henrik, A., Stenman, U.-H., Massobrio, M., van der Zee, A. G. J., Vergote, I., Diamandis, E. P. (2003). The Serum Concentration of Human Kallikrein 10 Represents a Novel Biomarker for Ovarian Cancer Diagnosis and Prognosis. Cancer Res. 63: 807-811 [Abstract] [Full Text]  
• Soma, L., Allen, M., Tobin, L., Ganster, C., Bulley, M., Hunt, J., Kricka, L. J., Senior, M., Kao, A. (2002). CA-125 Concentrations in Patients Awaiting Cardiac Transplantation. Clin. Chem. 48: 2289-2290 [Full Text]  
• Anderson, N. L., Anderson, N. G. (2002). The Human Plasma Proteome: History, Character, and Diagnostic Prospects. Mol. Cell. Proteomics 1: 845-867 [Abstract] [Full Text]  
• Bertholf, R. L., Johannsen, L., Benrubi, G. (2002). False Elevation of Serum CA-125 Level Caused by Human Anti-Mouse Antibodies. Annals of Clinical & Laboratory Science 32: 414-418 [Abstract] [Full Text]  
• Guppy, A.E., Rustin, G.J.S. (2002). CA125 Response: Can it Replace the Traditional Response Criteria in Ovarian Cancer?. The Oncologist 7: 437-443 [Abstract] [Full Text]  
• Devarbhavi, H., Kaese, D., Williams, A. W., Rakela, J., Klee, G. G., Kamath, P. S. (2002). Cancer Antigen 125 in Patients With Chronic Liver Disease. Mayo Clin Proc. 77: 538-541 [Abstract]  
• Sevinc, A., Sari, R., Buyukberber, S., Kwong, Y. L., Au, W. Y. (2001). Cancer Antigen 125: Tumor or Serosal Marker in Case of Ascites?. Arch Intern Med 161: 2507-2508 [Full Text]  
• Yousef, G. M., Kyriakopoulou, L. G., Scorilas, A., Fracchioli, S., Ghiringhello, B., Zarghooni, M., Chang, A., Diamandis, M., Giardina, G., Hartwick, W. J., Richiardi, G., Massobrio, M., Diamandis, E. P., Katsaros, D. (2001). Quantitative Expression of the Human Kallikrein Gene 9 (KLK9) in Ovarian Cancer: A New Independent and Favorable Prognostic Marker. Cancer Res. 61: 7811-7818 [Abstract] [Full Text]  
• Rustin, G. J.S., Marples, M., Nelstrop, A. E., Mahmoudi, M., Meyer, T. (2001). Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated Levels. JCO 19: 4054-4057 [Abstract] [Full Text]  
• Mills, G. B., Bast, R. C. Jr., Srivastava, S. (2001). Future for Ovarian Cancer Screening: Novel Markers From Emerging Technologies of Transcriptional Profiling and Proteomics. JNCI J Natl Cancer Inst 93: 1437-1439 [Full Text]  
• Mok, S. C., Chao, J., Skates, S., Wong, K.-k., Yiu, G. K., Muto, M. G., Berkowitz, R. S., Cramer, D. W. (2001). Prostasin, a Potential Serum Marker for Ovarian Cancer: Identification Through Microarray Technology. JNCI J Natl Cancer Inst 93: 1458-1464 [Abstract] [Full Text]  
• Jeong, Y.-Y., Outwater, E. K., Kang, H. K. (2000). Imaging Evaluation of Ovarian Masses. RadioGraphics 20: 1445-1470 [Abstract] [Full Text]  
• Gong, J., Nikrui, N., Chen, D., Koido, S., Wu, Z., Tanaka, Y., Cannistra, S., Avigan, D., Kufe, D. (2000). Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity. J. Immunol. 165: 1705-1711 [Abstract] [Full Text]  
• Epiney, M., Bertossa, C., Weil, A., Campana, A., Bischof, P. (2000). CA125 production by the peritoneum: in-vitro and in-vivo studies. Hum Reprod 15: 1261-1265 [Abstract] [Full Text]  
• Rustin, G. J. S., Nelstrop, A. E., Bentzen, S. M., Bond, S. J., McClean, P. (2000). Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II Trials. JCO 18: 1733-1739 [Abstract] [Full Text]  
• Gould, D. A., Moscoso, G. J., Young, M. P. A., Barton, D. P. J. (2000). Human First Trimester Fetal Ovaries Express Oncofetal Antigens and Steroid Receptors. Reproductive Sciences 7: 131-138 [Abstract]  
• Ahmed, A.S.M., Long, M., Donaldson, D. (2000). Lessons to be learned: a case study approach: Ascites and elevated serum CA 125 due to a pancreatic carcinoma. A diagnostic dilemma. The Journal of the Royal Society for the Promotion of Health 120: 47-51 [Abstract]  
• Petäjä, J., Pitkänen, S., Vettenranta, K., Fasth, A., Heikinheimo, M. (2000). Serum Tumor Marker CA 125 Is an Early and Sensitive Indicator of Veno-Occlusive Disease in Children Undergoing Bone Marrow Transplantation. Clin. Cancer Res. 6: 531-535 [Abstract] [Full Text]  
• Santala, M., Simojoki, M., Risteli, J., Risteli, L., Kauppila, A. (1999). Type I and Type III Collagen Metabolites as Predictors of Clinical Outcome in Epithelial Ovarian Cancer. Clin. Cancer Res. 5: 4091-4096 [Abstract] [Full Text]  
• Duska, L. R., Hamblin, M. R., Miller, J. L., Hasan, T. (1999). Combination Photoimmunotherapy and Cisplatin: Effects on Human Ovarian Cancer Ex Vivo. JNCI J Natl Cancer Inst 91: 1557-1563 [Abstract] [Full Text]  
• Robertson, D. M., Cahir, N., Burger, H. G., Mamers, P., McCloud, P. I., Pettersson, K., McGuckin, M. (1999). Combined Inhibin and CA125 Assays in the Detection of Ovarian Cancer. Clin. Chem. 45: 651-658 [Abstract] [Full Text]  
• Bridgewater, J. A., Nelstrop, A. E., Rustin, G. J.S., Gore, M. E., McGuire, W. P., Hoskins, W. J. (1999). Comparison of Standard and CA-125 Response Criteria in Patients With Epithelial Ovarian Cancer Treated With Platinum or Paclitaxel. JCO 17: 501-501 [Abstract] [Full Text]  
• van Ingen, H. E., Chan, D. W., Hubl, W., Miyachi, H., Molina, R., Pitzel, L., Ruibal, A., Rymer, J. C., Domke, I. (1998). Analytical and clinical evaluation of an electrochemiluminescence immunoassay for the determination of CA 125. Clin. Chem. 44: 2530-2536 [Abstract] [Full Text]  
• Xu, Y., Shen, Z., Wiper, D. W., Wu, M., Morton, R. E., Elson, P., Kennedy, A. W., Belinson, J., Markman, M., Casey, G. (1998). Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers. JAMA 280: 719-723 [Abstract] [Full Text]  
• Junghans, R. P., Carrasquillo, J. A., Waldmann, T. A. (1998). Impact of antigenemia on the bioactivity of infused anti-Tac antibody: Implications for dose selection in antibody immunotherapies. Proc. Natl. Acad. Sci. USA 95: 1752-1757 [Abstract] [Full Text]  
• Sheets, E. E., Smith, R. N. (1998). Case 3-1998- A 31-Year-Old Woman with a Pleural Effusion, Ascites, and Persistent Fever Spikes. NEJM 338: 248-254 [Full Text]  
• Eagle, K., Ledermann, J. A. (1997). Tumor Markers in Ovarian Malignancies. The Oncologist 2: 324-329 [Abstract] [Full Text]  
• Flyvbjerg, A., Mogensen, O., Mogensen, B., Nielsen, O. S. (1997). Elevated Serum Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2) and Decreased IGFBP-3 in Epithelial Ovarian Cancer: Correlation with Cancer Antigen 125 and Tumor-Associated Trypsin Inhibitor. J. Clin. Endocrinol. Metab. 82: 2308-2313 [Abstract] [Full Text]  
• Bonfrer, J. M. G., Korse, C. M., Verstraeten, R. A., van Kamp, G. J., Hart, G. A. M., Kenemans, P. (1997). Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference value. Clin. Chem. 43: 491-497 [Abstract] [Full Text]  
• Markman, M. (1997). The Role of CA-125 in the Management of Ovarian Cancer. The Oncologist 2: 6-9 [Abstract] [Full Text]  
• Craver, R. D., Golladay, S. E., Warrier, R. P., Gates, A. J., Nelson, J. S. (1996). Neurocutaneous Melanosis With Dandy-Walker Malformation Complicated by Primary Spinal Leptomeningeal Melanoma. J Child Neurol 11: 410-414  
• Moncayo, R., Moncayo, H. E (1995). A new endocrinological and immunological syndrome in SLE: elevation of human chorionic gonadotropin and of antibodies directed against ovary and endometrium antigens. Lupus 4: 39-45 [Abstract]  
• Konishi, I., Fendrick, J. L., Parmley, T. H., Quirk, J. G. JR, O'Brien, T. J. (1994). Epidermal Growth Factor Enhances Secretion of the Ovarian Tumor-Associated Cancer Antigen CAI25 From the Human Amnion WISH Cell Line. Reproductive Sciences 1: 89-96 [Abstract]  
• Healy, D. L., Burger, H. G., Mamers, P., Jobling, T., Bangah, M., Quinn, M., Grant, P., Day, A. J., Rome, R., Campbell, J. J. (1993). Elevated Serum Inhibin Concentrations in Postmenopausal Women with Ovarian Tumors. NEJM 329: 1539-1542 [Abstract] [Full Text]  
• Cannistra, S. A. (1993). Cancer of the Ovary. NEJM 329: 1550-1559 [Full Text]  
• Gocze, P. M., Freeman, D. A. (1993). CA-125 as a Screening Test for Ovarian Cancer. JAMA 269: 3106-3106 [Abstract]  
• Helzlsouer, K. J., Alberg, A. J., Bush, T. L., Comstock, G. W. (1993). CA-125 as a Screening Test for Ovarian Cancer-Reply. JAMA 269: 3106-3107 [Abstract]  
• Schapira, M. M., Matchar, D. B., Young, M. J. (1993). The Effectiveness of Ovarian Cancer Screening: A Decision Analysis Model. ANN INTERN MED 118: 838-843 [Abstract] [Full Text]  
• Helzlsouer, K. J., Bush, T. L., Alberg, A. J., Bass, K. M., Zacur, H., Comstock, G. W. (1993). Prospective Study of Serum CA-125 Levels as Markers of Ovarian Cancer. JAMA 269: 1123-1126 [Abstract]  
• Bates, S. E. (1991). Clinical Applications of Serum Tumor Markers. ANN INTERN MED 115: 623-638 [Abstract]  
• Markman, M., Hoskins, W. B. (1989). Ovarian Cancer, Inflammation, and CA-125. ANN INTERN MED 111: 1049-1049 [Abstract]  
• MUGGIA, F. M., PICCART, M. J., SPEYER, J. L. (1985). Ovarian Cancer: New Therapeutic Concepts, Renewed Optimism. ANN INTERN MED 103: 795-797 [Abstract]